Search - tctmd.com

Displaying 201 - 220 of 320

Sort: Relevancy | Date

News Daily News

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

Caitlin E. Cox

May 03, 2022

News Daily News

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

Michael O'Riordan

April 29, 2022

News Daily News

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Michael O'Riordan

April 22, 2022

News Daily News

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Todd Neale

April 20, 2022

News Daily News

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

Caitlin E. Cox

April 15, 2022

News Conference News ACC 2022

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

L.A. McKeown

April 03, 2022

News Conference News ACC 2022

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

Shelley Wood

April 03, 2022

News Conference News ACC 2022

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Shelley Wood

April 01, 2022

News Daily News

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

L.A. McKeown

March 22, 2022

News Daily News

Guideline-Directed Therapies Underused in Frail HF Patients

L.A. McKeown

March 11, 2022

News Conference News THT 2022

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

L.A. McKeown

February 07, 2022

News Conference News STS 2022

Modified Surgical MV Repair Stands Up to Replacement

Michael O'Riordan

February 03, 2022

News Daily News

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Michael O'Riordan

January 27, 2022

News Daily News

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Todd Neale

January 21, 2022

News Daily News

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

L.A. McKeown

December 07, 2021

News Conference News AHA 2021

Canagliflozin Improves Quality of Life in HF Patients

Michael O'Riordan

November 16, 2021

News Conference News AHA 2021

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

Shelley Wood

November 14, 2021

News Conference News TCT 2021

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

Michael O'Riordan

November 06, 2021

News Opinion CV Team Dispatch

November 2021 News Roundup

L.A. McKeown

November 01, 2021

News Daily News

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Todd Neale

October 20, 2021

Advertisement

Frailty Does Not Hinder Dapagliflozin’s HFrEF Impact: DAPA-HF Analysis

FDA Approves Mavacamten for Obstructive Hypertrophic Cardiomyopathy

CVD Hospitalizations Spiked in Aftermath of 2020 US Election

Underuse of GDMT for Heart Failure Even Worse in Low-Income Countries

Revascularization’s Benefits in HFrEF Linked to Gains in LV Function

PROMPT-HF: Pop-up Alerts Improve HFrEF Medication Optimization

Mavacamten Yields Stable Benefits in Obstructive HCM Over Longer Term

New HF Guidelines Stress Four-Drug Approach, ‘HFmrEF,’ Amyloidosis Options, and More

Empagliflozin Plus an MRA Is Safe in HFpEF, May Help With Hyperkalemia

Guideline-Directed Therapies Underused in Frail HF Patients

Probe Beyond Ejection Fraction to Understand and Manage HFpEF

Modified Surgical MV Repair Stands Up to Replacement

In the US, HF Prevalence—and Costs—Rising Steeply: HFSA Report

Journal of Cardiac Failure Launches Rapid Publication Platform to Spark Discourse

Meta-analysis of Pivotal SGLT2 Inhibitor Trials Boosts Hopes in HFpEF

Canagliflozin Improves Quality of Life in HF Patients

Empagliflozin Safe in Acute HF, Improves ‘Clinical Benefit’ Over Time: EMPULSE

GUIDE-HF Hints That Hemodynamic-Guided Management Works in HFpEF

November 2021 News Roundup

As Amyloidosis Field Explodes, Physicians Need to Spot and Treat

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content